Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by the Veeva Development Cloud, designed to accelerate the global ...

Boehringer Ingelheim, GoodRx team to boost access to Humira biosimilars By Paige Minemyer Jul 18, 2024 3:00pm GoodRx Boehringer Ingelheim Drug Prices biosimilars ...

This release is available in German. Ebersberg/Biberach an der Riss, September 16, 2010. Boehringer Ingelheim Pharma GmbH & Co. KG, an international research-driven pharma company, and Eurofins ...

Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.

Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev. February ...

Boehringer Ingelheim already entered into a partnership with GST in 2018; in 2019, the companies launched Arti-Cell ® Forte in Europe. Arti-Cell ® Forte is testimony to the innovation strength ...

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ($31.06 million) to a new R&D facility specifically focused on the modality.

W ASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less ...

Boehringer Ingelheim has spruced up its image, rolling out new corporate branding that features its “first-ever brand claim” and a “standout color palette” dominated by different green hues.

Boehringer Ingelheim says weight-loss drug had positive impact on liver condition on whatsapp (opens in a new window) Save Ian Johnston in London. Published February 26 2024.

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...